miR-29a expression is downregulated by SMAD3 via TGF-β/SMAD signaling in SSc, which has been confirmed by protection against bleomycin or TGF-β1-induced loss of miR-29a along with fibrosis in SMAD3-null models [25]. Here, SMAD3 is linked to systemic sclerosis.